Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) EPS (Basic) (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed EPS (Basic) for 10 consecutive years, with -$1.22 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 44.55% to -$1.22 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.96 through Dec 2025, up 48.15% year-over-year, with the annual reading at -$1.96 for FY2025, 44.16% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$1.22 at Rein Therapeutics, down from -$0.21 in the prior quarter.
  • The five-year high for EPS (Basic) was -$0.06 in Q2 2021, with the low at -$5.67 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$1.05, with a median of -$0.66 recorded in 2024.
  • The sharpest move saw EPS (Basic) crashed 4625.0% in 2021, then soared 82.36% in 2022.
  • Over 5 years, EPS (Basic) stood at -$5.67 in 2021, then skyrocketed by 82.36% to -$1.0 in 2022, then tumbled by 57.0% to -$1.57 in 2023, then tumbled by 40.13% to -$2.2 in 2024, then surged by 44.55% to -$1.22 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$1.22, -$0.21, and -$0.28 for Q4 2025, Q3 2025, and Q2 2025 respectively.